At the end of 2023, Israeli insurance and finance group The Phoenix Holdings’ stake in Teva was 5.4%.
Insurance and finance group The Phoenix Holdings (TASE: PHOE) has become a party at interest in Teva Pharmaceutical Industries (TASE: TEVA; NYSE: TEVA). The Phoenix had a holding of 5.4% in Teva at the end of 2023, today’s company filing with the US Securities and Exchange Commission (SEC) reveals.
The Phoenix holds 60.5 million shares in Teva, currently worth $732 million. According to the filing, The Phoenix holds the shares through several subsidiaries. As a passive investor, The Phoenix is not obliged to report when it bought the shares and at what prices. Teva’s share price ranged between $7.2 and $11.4 in 2023. The current price is $12.38, giving the company a market cap of $13.9 billion.
RELATED ARTICLES
Teva to sell API activity, beats analysts on Q4
The Phoenix is currently the only party at interest in Teva (ie, has a holding of 5% or more). In recent years, parties at interest in the company were mainly overseas entities. Until not long ago, US investment company Capital Research was the largest shareholder in Teva, with a holding of 10.3%, but it sold all of its Teva shares in April-May 2023.
Published by Globes, Israel business news – en.globes.co.il – on February 1, 2024.
© Copyright of Globes Publisher Itonut (1983) Ltd., 2024.
Teva’s R&D labs in Netanya credit: Teva PR
Maya Levin and Shiri Habib-Valdhorn
